SCHEMBL30786170

SCHEMBL30786170

O=C(NC1CC1)c1cccc(F)c1S

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 1/20 0.54
HPGD P15428 5/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
ALDH1A1 P00352 4/20 0.46
NPC1 O15118 3/20 0.46
KDM4E B2RXH2 2/20 0.46
RAB9A P51151 2/20 0.46
LMNA P02545 2/20 0.46
HTT P42858 1/20 0.46
GRM5 P41594 1/20 0.45
TAS1R3 Q7RTX0 1/20 0.45
TAS1R1 Q7RTX1 1/20 0.45
TAS1R2 Q8TE23 1/20 0.45
GAA P10253 2/20 0.44
MAPT P10636 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
POLB P06746 1/20 0.43
ALOX12 P18054 1/20 0.43
MEN1 O00255 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3170903 0.83 P2RX7 (0.57) P2RX7HPGDL3MBTL1ALDH1A1NPC1
SCHEMBL363351 0.83 NPC1 (0.60) P2RX7HPGDALDH1A1NPC1KDM4E
SCHEMBL3172457 0.81 TAS1R3 (0.59) P2RX7HPGDL3MBTL1ALDH1A1NPC1
SCHEMBL738909 0.81 P2RX7 (0.71) P2RX7HPGDL3MBTL1ALDH1A1NPC1
SCHEMBL23462319 0.77 NPC1 (0.55) P2RX7ALDH1A1NPC1RAB9ALMNA
SCHEMBL23462320 0.77 NPC1 (0.55) P2RX7ALDH1A1NPC1RAB9ALMNA
SCHEMBL28465600 0.77 NPC1 (0.66) HPGDALDH1A1NPC1KDM4ERAB9A
SCHEMBL10278648 0.77 GRM5 (0.64) HPGDALDH1A1NPC1KDM4ERAB9A
SCHEMBL30786110 0.76 GAA (0.67) HPGDALDH1A1NPC1RAB9ALMNA
SCHEMBL30786087 0.76 GAA (0.67) HPGDALDH1A1NPC1RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260049071-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF BEYANG THERAPEUTICS CO LTD (CN) 2026-02-19 US disclosed
EP-4556466-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF Beyang Therapeutics Co., Ltd. (CN) 2025-05-21 EP disclosed
WO-2025082316-A1 OPHTHALMIC FORMATION, AND PREPARATION METHOD THEREFOR AND USE THEREOF 苏州必扬医药科技有限公司 2025-04-24 WO disclosed
CN-119604488-A Protein tyrosine kinase inhibitor and medical application thereof 苏州必扬医药科技有限公司 2025-03-11 CN disclosed
WO-2024032584-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF 苏州必扬医药科技有限公司 2024-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260049071-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF KDR, FLT1, ERBB2 P2RX7 4242/4885HPGD 3521/4885L3MBTL1 607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.